[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369981-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369981-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genetically-platform-presenting-cd24-scfv-enhance-antitumor-immunity-by-restoring-macrophage-phagocytosis-and-modulating-the-immune-environment","Genetically platform presenting CD24 scFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment","","Immunotherapy success depends on overcoming tumor immune suppression, where macrophages shape homeostasis and antitumor clearance. Blocking the CD24–Siglec-10 axis is known to enhance macrophage phagocytosis, but therapeutic strategies that reprogram this interaction remain to be optimized. This study uses GEO data and clinical samples to identify CD24 as an overexpressed molecule in ovarian and breast cancer and develops genetically programmable extracellular vesicles displaying CD24 single-chain variable fragment (CD24 scFv-EVs). CD24 scFv-EVs restore macrophage phagocytic activity, enhance clearance of CD24-overexpressing cancer cells, inhibit the CD24–Siglec-10 pathway, and promote macrophage polarization toward an M1-like phenotype.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genetically-platform-presenting-cd24-scfv-enhance-antitumor-immunity-by-restoring-macrophage-phagocytosis-and-modulating-the-immune-environment/369981/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genetically-platform-presenting-cd24-scfv-enhance-antitumor-immunity-by-restoring-macrophage-phagocytosis-and-modulating-the-immune-environment/369981.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecule and immune pathway does the study target?","Question",{"text":63,"@type":64},"The study targets CD24 and its inhibitory pathway with Siglec-10. CD24 scFv-EVs are designed to block this interaction.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CD24-overexpressing cancers identified?",{"text":68,"@type":64},"CD24 overexpression in ovarian and breast cancer was identified using data from the GEO database together with clinical samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the therapeutic effect of CD24 scFv-EVs?",{"text":72,"@type":64},"CD24 scFv-EVs restore macrophage phagocytic activity and eliminate CD24-overexpressing cancer cells by inhibiting the CD24–Siglec-10 pathway, and they promote an M1-like macrophage phenotype.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369981,1790813427,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Zhou et al. Cell Communication and Signaling (2025) 23:517  \n[https://doi.org/10.1186/s12964-025-02486-4](https://doi.org/10.1186/s12964-025-02486-4)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nGenetically platform presenting CD24 ScFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment  \nGuannan Zhou 1*†, Yuanyuan Gu 1†, Menglei Zhang 1†, Hang Zhou 1, Yao Li2, Xiaoyan Lin3, Guanming Lu4,5,6*†, Fang Shen 1*†, Cheng Xu3*†, Keqin Hua 1*† and Jingxin Ding 1*†  \nAbstract  \nImmunotherapy has achieved remarkable progress in treating cancers that evade immune surveillance. Among the components of the tumor microenvironment, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, engulfing and promoting the adaptive immune response. It is acknowledged that blocking the CD24–Siglec-10 interaction significantly enhances the macrophage phagocytosis ability. In this study, we identified CD24 as an over-expressed molecule in ovarian and breast cancer using data from the GEO database and clinical samples. We then developed genetically programmable extracellular vesicles displaying CD24 singlechain variable fragment (CD24 scFv-EVs) and evaluated their ability to restore macrophage phagocytic activity and eliminate CD24-overexpressing cancer cells. Our findings demonstrate that CD24 scFv-EVs effectively block CD24 on ovarian cancer cells as well as breast cancer cells, thereby inhibiting the CD24–Siglec-10 pathway and enhancing macrophage-mediated clearance of cancer cells. Furthermore, CD24 scFv-EVs promote the polarization  \n\n| †Guannan Zhou, Yuanyuan Gu and Menglei Zhang contributed equally to this work. |\n| --- |\n| Guannan Zhou, Guanming Lu, Fang Shen, Cheng Xu, Keqin Hua and Jingxin Ding contributed equally to this work as corresponding author. |\n\n*Correspondence:  \nGuannan Zhou [zgnsmmu@163.com](zgnsmmu@163.com)[ ](zgnsmmu@163.com)Guanming Lu[luguanming@ymcn.edu.cn](luguanming@ymcn.edu.cn)[ ](luguanming@ymcn.edu.cn)Fang Shen [shenfang1213@126.com](shenfang1213@126.com)[ ](shenfang1213@126.com)Cheng Xu  \n[xucheng@live.cn](xucheng@live.cn)  \nKeqin Hua [huakeqinjiaoshou@163.com](huakeqinjiaoshou@163.com)[ ](huakeqinjiaoshou@163.com)Jingxin Ding [djxdd@sina.com](djxdd@sina.com)  \nFull list of author information is available at the end of the article  \nIntroduction  \nThe intricate cell interactions and communications between tumor cells and neighboring immune cells involves complex competitive-cooperative patterns rewired through immune signals, which are essential for shaping the immunosuppressive tumor microenvironment (TME) [1]. It is vital to exploit the novel therapeutic strategies based on the cross-talks and communications among the tumor microenvironments.  \nOvarian cancer is the most challenging malignancies in reproductive system and remains the leading cause of gynecologic cancer-related deaths [2]. While debulking surgery combined with platinum-based chemotherapy is the standard treatment, recurrence occurs in 25% to 80% of patients highlighting the urgent need for more effective therapeutic strategies [3, 4].  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by ","cbCaigbRIaKV4cqi","https://ap.wps.com/l/cbCaigbRIaKV4cqi","pdf",8956898,"English","# Abstract\n# Introduction\n## Tumor microenvironment and immune cell communication\n## Ovarian cancer treatment challenges\n## Breast cancer background and heterogeneity\n## Immune checkpoint therapies and the CD24–Siglec-10 axis\n# Keywords","[{\"question\":\"What molecule and immune pathway does the study target?\",\"answer\":\"The study targets CD24 and its inhibitory pathway with Siglec-10. CD24 scFv-EVs are designed to block this interaction.\"},{\"question\":\"How were CD24-overexpressing cancers identified?\",\"answer\":\"CD24 overexpression in ovarian and breast cancer was identified using data from the GEO database together with clinical samples.\"},{\"question\":\"What is the therapeutic effect of CD24 scFv-EVs?\",\"answer\":\"CD24 scFv-EVs restore macrophage phagocytic activity and eliminate CD24-overexpressing cancer cells by inhibiting the CD24–Siglec-10 pathway, and they promote an M1-like macrophage phenotype.\"}]","Genetically platform presenting CD24 scFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment | PDF",1790185991,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f58b4511a9a6d9d4a1cdcb4d299b209.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2be9bf82489825920dd59b6abae46371.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4db8cbc10a0add8411f064c1bd7d8321.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f3410f78adf2848c787f8c09c4040c6.webp",980,1306]